Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was down 4.2% on Friday . The company traded as low as $10.25 and last traded at $10.63, with a volume of 639,769 shares changing hands. The stock had previously closed at $11.10.

Several research analysts have weighed in on KPTI shares. S&P Equity Research lowered their price objective on Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. HC Wainwright started coverage on Karyopharm Therapeutics in a research report on Thursday, August 18th. They set a “buy” rating and a $15.00 price objective on the stock. Canaccord Genuity set a $20.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 6th. Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Monday, June 27th. Finally, Jefferies Group upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the stock from $9.00 to $12.00 in a research report on Tuesday, August 30th. Two investment analysts have rated the stock with a sell rating and eleven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $15.97.

The firm’s 50 day moving average is $7.47 and its 200-day moving average is $7.99. The firm’s market cap is $382.20 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. On average, equities research analysts predict that Karyopharm Therapeutics Inc. will post ($3.26) EPS for the current fiscal year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 45,541 shares of the business’s stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $9.21, for a total value of $419,432.61. Following the transaction, the insider now owns 8,605,818 shares of the company’s stock, valued at $79,259,583.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.